These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 28579758)
21. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery. Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909 [TBL] [Abstract][Full Text] [Related]
22. A functionalized graphene oxide with improved cytocompatibility for stimuli-responsive co-delivery of curcumin and doxorubicin in cancer treatment. Yaghoubi F; Motlagh NSH; Naghib SM; Haghiralsadat F; Jaliani HZ; Moradi A Sci Rep; 2022 Feb; 12(1):1959. PubMed ID: 35121783 [TBL] [Abstract][Full Text] [Related]
23. An improved method in fabrication of smart dual-responsive nanogels for controlled release of doxorubicin and curcumin in HT-29 colon cancer cells. Abedi F; Davaran S; Hekmati M; Akbarzadeh A; Baradaran B; Moghaddam SV J Nanobiotechnology; 2021 Jan; 19(1):18. PubMed ID: 33422062 [TBL] [Abstract][Full Text] [Related]
24. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
25. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets. Baghbani F; Moztarzadeh F Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723 [TBL] [Abstract][Full Text] [Related]
26. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes. Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642 [TBL] [Abstract][Full Text] [Related]
27. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959 [TBL] [Abstract][Full Text] [Related]
28. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy. Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944 [TBL] [Abstract][Full Text] [Related]
29. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845 [TBL] [Abstract][Full Text] [Related]
30. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Zhao X; Chen Q; Liu W; Li Y; Tang H; Liu X; Yang X Int J Nanomedicine; 2015; 10():257-70. PubMed ID: 25565818 [TBL] [Abstract][Full Text] [Related]
31. Vascular targeting of doxorubicin using cationic liposomes. Wu J; Lee A; Lu Y; Lee RJ Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230 [TBL] [Abstract][Full Text] [Related]
32. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design. Yang B Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868 [TBL] [Abstract][Full Text] [Related]
33. Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. Roque MC; Franco MS; Vilela JMC; Andrade MS; de Barros ALB; Leite EA; Oliveira MC Curr Drug Deliv; 2019; 16(9):829-838. PubMed ID: 31622204 [TBL] [Abstract][Full Text] [Related]
34. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. Abouzeid AH; Patel NR; Rachman IM; Senn S; Torchilin VP J Drug Target; 2013 Dec; 21(10):994-1000. PubMed ID: 24098980 [TBL] [Abstract][Full Text] [Related]
35. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment. Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348 [TBL] [Abstract][Full Text] [Related]
36. Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. Dash TK; Konkimalla VB Pharm Res; 2017 Aug; 34(8):1741-1750. PubMed ID: 28536971 [TBL] [Abstract][Full Text] [Related]
37. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502 [TBL] [Abstract][Full Text] [Related]
38. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo. Nguyen VD; Min HK; Kim CS; Han J; Park JO; Choi E Colloids Surf B Biointerfaces; 2019 Jan; 173():539-548. PubMed ID: 30343218 [TBL] [Abstract][Full Text] [Related]
39. [Preparation of curcumin-loaded long-circulating liposomes and its pharmacokinetics in rats]. You J; Dai DB; He WJ; Li G; Song SC; Wei YH; Li FZ; Xu XL Zhongguo Zhong Yao Za Zhi; 2014 Apr; 39(7):1238-42. PubMed ID: 25011261 [TBL] [Abstract][Full Text] [Related]
40. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Luo D; Carter KA; Razi A; Geng J; Shao S; Giraldo D; Sunar U; Ortega J; Lovell JF Biomaterials; 2016 Jan; 75():193-202. PubMed ID: 26513413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]